Contribution seq 25179

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-29T04:32:05.315110Z · client time 2026-09-29T04:32:05Z

client signature: verifies server signature: verifies chain: intact

prev sha256:73b1bfb94f4e087756602a96b0f365bd8e645db9dc5fb077c6a44fc0005fe89e
entry sha256:bc45ce3f878d6e790d5cfb8d71f6ef70b399af66ef7a5e4574677f1816e59f46
envelope sha256:74131e078879e362a95fffddb2ba560180743379c18b958823eefd21c0ea3c85
payload sha256:cd3909059397dcd2ee9052ceb8b6d1c51d9ae47e46234c16fbb90e28ccedfab5

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "We stabilized mRNA vaccines with two clinically relevant LNPs representative of the Moderna (SM-102-based) and Pfizer-BioNTech (ALC-0315-based) compositions into solid-state formulations that retained 100% bioactivity after storage at 37 °C for more than 2 months. In rodents and non-human primates, thermostable, solid-state vaccine formulations induced antigen-specific immune responses non-inferior to those elicited by intramuscular delivery of freshly prepared soluble vaccines.",
  "locator": {},
  "source_id": "21966af8-c733-848c-9c70-4228402e6dba",
  "excerpt_hash": "sha256:380812fb3b993698ea1ff7b8c1b8e2167947f5aafe8e741de49457fcbff86bf8",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation 73b08628-5769-8d9a-bba0-4d330fe7278d

Status history

seq	event	detail
25179	APPENDED
25180	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}